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The  hybridoma  technology  (1)  has  made  it  possible  to  generate  immunological 
reagents that are in many ways superior to antisera obtained through conventional 
immunization  (2).  Cell lines secreting monoclonal antibodies provide large amounts 
of well-defined homogeneous reagents that can be replenished indefinitely. Whenever 
a  battery of different monoclonals is available for an antigen,  it is possible to select 
the ones best suited for particular assays (3).  Unfortunately, some of the properties of 
antibodies complicate their use in research and might be a barrier to their fullest use 
in diagnosis and therapy. For example, antibody binding to complement and to Fc 
receptors on lymphocytes and phagocytic cells forms the basis of many immunoassays 
but  is a  constant  problem in  immunofluorescence experiments and  might seriously 
hamper  attempts  to  use  monoclonals  in  vivo.  The  approach  to  overcoming such 
problems with conventional antibodies has usually involved proteolytically removing 
the Fc portion of the molecule. Because monoclonal antibodies are produced by cells 
in culture, we thought  it might be possible to identify mutant  subclones producing 
structurally  altered  antibodies  using  techniques  previously  developed  to  identify 
somatic mutants in mouse myeloma cells (4,  5).  One purpose in these studies was to 
determine whether similar techniques could identify mutant monoclonal antibodies 
with defects in those properties that limit the usefulness of the intact molecule. 
In addition  to their  benefits as serological reagents,  monoclonal  antibodies  offer 
advantages over myeloma proteins  for studying immunoglobulin  synthesis  and  the 
structural basis of antibody effector functions. Because most myeloma proteins do not 
bind  known  antigens,  these  immunoglobulins  or  fragments  of  them  have  been 
artificially aggregated to simulate antigen-antibody complexes that fix complement 
or bind to Fc receptors (6).  Now that it is possible to generate monoclonal antibodies 
of all classes that react with convenient antigens, homogeneous immunoglobulins can 
be  purified  by  antigen  affinity  chromatography  and  activated  physiologically  by 
forming immune complexes. Although  mutant  human  (7)  and mouse myeloma (8) 
proteins have been useful in studying antibody functions, structurally altered mono- 
clonal  antibodies  should  provide additional  information  on  the  structural  basis  of 
effector functions. 
In this paper, we show that a  hybridoma producing an IgG2b antibody that binds 
p-azophenylarsonate (gr) 1 generates somatic mutants producing antibody molecules 
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with deletions in various parts of the Fc region. These mutants arise frequently after 
mutagenesis.  The  mutant  immunoglobulin molecules  exhibit  aberrant  assembly 
patterns and have lost the ability to carry out certain effector functions. In addition, 
we report generating a battery of rat monoclonal antibodies that react with different 
domains of the IgG2b constant region and are useful in locating the deletions in the 
mutant monoclonal antibodies. 
Materials and Methods 
Cell Lines.  All myeloma and hybridoma cell lines were maintained in Dulbecco's modified 
Eagle's medium (Gibco Laboratories, Grand Island Biological Co., Grand Island, NY) contain- 
ing 10% fetal  calf serum (FCS)  in a  humidified atmosphere of 5-10% CO2. The M3.11  and 
B50-10.1 mutant lines from the MPC-11 myeloma have been reported previously (9-12). B50- 
10.1 was kindly provided by Dr.  Sherie Morrison of Columbia University, New York.  The 
methods for producing hybrid cell lines have been reported in detail (13). The X63-Ag8.653 
myeloma cell line that synthesizes  no immunoglobulin chains (14) was  used to produce the 
hybrids reported here.  The Ar13.4  anti-azophenylarsonate, IgG2bK hybridoma was obtained 
by fusing splenic lymphocytes from a  BALB/c mouse immunized with p-azophenylarsonate 
attached to keyhole limpet hemocyanin (Ar:KLH) by the method of Nisonoff (15). 250/~g of 
Ar:KLH in complete Freund's adjuvant was injected intraperitoneally, followed  by a boost 4 
wk later of 250 #g Ar:KLH in saline intravenously. Immunizations and fusions generating 
hybridomas secreting rat monoclonal anti-IgG2b antibodies have been reported (16). Rat Mab 
187, 116, 180, and 168 were derived from a Sprague-Dawley rat; 31,178 and 196 were derived 
from a Lewis rat. All cell lines have been subcloned to insure clonality. 
Rabbit Antisera.  Rabbits were immunized (17) with purified MPC-11 myeloma protein (18). 
Antisera specific for restricted parts of the y2b heavy chain were obtained by passing the rabbit 
antisera over a column to which purified immunoglobulin had been attached by activating 
Sepharose  4B  (Pharmacia Fine Chemicals, Div.  of Pharmacia  Inc.,  Piscataway,  N  J)  with 
cyanogen bromide (CNBr)  (19). Antiserum defined as  "specific"  for  the IgG2b subclass was 
extensively absorbed with an affinity-purified IgG2a anti-Ar monoclonal antibody. Antiserum 
specific  for  the CH3 domain was  absorbed with purified M3.11  protein. Both antisera were 
considered fully absorbed when they could not hemagglutinate sheep erythrocytes  (SRBC) 
coated with the absorbing protein. 
Selecting H-Chain Mutants.  The method of selecting heavy chain (H-chain) mutants from 
Ar13.4 was adapted from that used previously to select variants from the MPC-11 cell line (4, 
5). Cells were mutagenized for 24 h with 2.5 #g/ml of the acridine half-mustard ICR-191 (20). 
After 48 h, ~30% of the original number of cells remained viable, as judged by trypan blue 
exclusion. The cells  were  then cloned in soft  agarose  (500-1,000 clones/60-mm petri  dish) 
containing 100/~1 of antisera specific for a restricted segment of the constant region of IgO2b. As 
the clones reached the 8-32 cell stage,  a  visible antigen-antibody precipitate formed around 
clones secreting immunoglobulin  still reactive with the antiserum. Clones without any precip- 
itate were marked as putative variants. Clones were marked by inserting three pieces of sterile 
costume glitter into the agarose forming an asymmetric triangle. Under microscopic visualiza- 
tion, marks were placed above the glitter on the dish cover using a fine felt-tipped marker with 
water-insoluble ink. Unstained clones were also  marked on the dish cover and relocated by 
reorienting the  dish cover using the  glitter. After unstained clones were  identified, agarose 
containing  an unabsorbed antiserum (50/~l/dish) reactive with the entire IgG2b constant region 
was layered over the clones. This must be done before the clones reach the 100-200 cell stage. 
Clones that did not react with the first antiserum but did react with the second were likely to 
be producing mutant immunoglobulins. Although this double overlay scheme does not com- 
pletely eliminate picking false positive and false negative clones and requires some technical 
finesse, it has proved superior to attempts at brute force recovery and screening of all clones 
unreactive with the restricted antiserum. 
Proteins.  Production of ascites  (21) and purification of myeloma proteins (18) have been 
described. Proteins from the Ar13.4 parent and mutant hybridomas were purified by affinity 
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4B  to which a  gly-tyr dipeptide (Calbiochem-Behring Corp., American Hoechst Corp., San 
Diego,  CA) had been attached with CNBr and subsequently conjugated with p-azophenylar- 
sonate. Adsorption of antibody to the column was carried out overnight at 4°C in the presence 
of 0.5  M  NaCI and 0.5% Nonidet P-40  (Shell  Oil Co.,  Houston, TX). The Sepharose was 
washed  thoroughly with Tris-saline (0.15  M  NaCI;  25  mM Tris, pH  7.5). Antibodies were 
eluted with 50 mM p-azophenylarsonate  in Tris-saline, dialyzed exhaustively to remove hapten, 
concentrated to ~ i0 mg/ml using an Amicon PM-10 membrane (Amicon Corp., Lexington, 
MA), made 10 mM with NAN3, and stored at 4°C. Some mutant proteins are secreted in low 
amounts and appear to have a short half-life in vivo, making purification of more than a few 
milligrams laborious. 
Radioimmunoassay.  Methods for endogeneously labeling monoclonal antibodies by growing 
hybridomas in ~S (or 14C) amino acids have been described (16). After dialysis to remove the 
unincorporated label, the culture supernatants can be used in radioimmunoassays without 
further purification. Radioimmunoassays  used in these experiments are patterned after those of 
Pierce and Klinman (22). The wells of round-bottomed polyvinyl chloride microtiter dishes 
(Dynatech Laboratories, Inc., Dynatech Corp.,  Alexandria, VA)  were coated  with  antigen 
(either Ar:KLH or purified immunoglobulin)  by adsorption overnight at 4°C of 100/~1 of a  10 
pg/ml solution of antigen diluted in PBS (0.15 M NaCI; 20 mM Na PO4, pH 6.8). Wells were 
washed thoroughly with PBS and filled with a solution of 1% bovine serum albumin (BSA- 
Pentex) in PBS for 2 h at 25°C to block unreacted sites. These antigen-coated wells can be used 
in sandwich assays  to detect antibody to the antigen or in inhibition assays  to examine the 
specificity ofa monoclonal (see figure legends for details). For either assay, subsequent antibody- 
binding incubations were carried out overnight at 4°C. Antibodies were diluted with 1% BSA 
in PBS. After being washed with the PBS-BSA,  wells were cut out and counted in a Beckman 
scintillation counter (Beckman Instruments, Inc., Fullerton, CA). 
Hemagglutination Assays.  Two types of hemagglutination assays were used in these experi- 
ments and have been described (16). The first,  designated "facilitated hemagglutination," is 
designed to  quantitate roughly the  amount of anti-azophenylarsonate antibody (Ar13.4  or 
mutant)  in solution. Because  the  Ar13.4  antibody and some other  monoclonals are  weak 
agglutinins and many mutants secrete  HL half-molecules incapable of cross-linking erythro- 
cytes, a rabbit anti-mouse immunoglobulin  serum was added to promote cross-linking via the 
monoclonal antibody bound to Ar:SRBC (see below). 
The second assay is an inhibition  of hemagglutination assay designed to determine whether 
the "inhibiting"  protein contains determinants  recognized by an antibody (Mab or conventional 
antiserum). If a  protein is recognized, it will compete with the antigen on the  SRBC  and 
prevent agglutination. This assay is modified from Evans et al.  (23). 
The antigen-SRBC used for titering anti-Ar antibodies was conjugated with p-azophenylar- 
sonate (15) using 20 pmoles p-azophenylarsonate per ml of packed SRBC (Ar:SRBC). The cells 
were fixed with glutaraldehyde (13) and stored at 4°C in PBS with  10 mM NaN3  for up to 
several weeks. Antigen-SRBC used in inhibition of hemagglutination assays  contained IgG~b 
fixed onto the SRBC with glutaraldehyde and stored as above. The IgG2b protein was from an 
anti-SRBC hybridoma that does not agglutinate SRBC, even at very high concentrations. This 
permitted a large amount of IgG2b to be fixed to the SRBC, improving the sensitivity of the 
assay. All solutions were diluted into PBS containing I% (wt/vol) BSA. 
Polyacrylamide Gel Analysis of Biosynthetically Labeled Immunoglobulin.  Conditions for  labeling 
cells were similar to those previously described (24). 25/~Ci of [35S]methionine  (New England 
Nuclear,  Boston,  MA)  was  used  per  106  viable cells.  Incorporation times  for  intracellular 
material was 2 h and for secreted material 5 h, unless noted otherwise. Labeled immunoglobulins 
were precipitated either by indirect immunoprecipitation (25) or by adsorption onto 50 #1 of 
haptenated Sepharose 4B. Because both methods gave identical results with all mutants, the 
latter  method  was  generally used  for  convenience. After washing,  immune precipitates or 
Sepharose were boiled in 2% SDS in electrophoresis sample buffer (26) for 2 min. Reduction 
was carried out with 10 mM dithiothreitol (Sigma Chemical Co., Saint-Louis, MO) for 2 h at 
37°C, followed  by alkylation for  1 h  at  37°C with a  twofold molar excess of iodoacetamide 
(Sigma Chemical Co.)  recrystallized from absolute ethanol. See  figure legends for details of 
electrophoresis conditions. When labeling was done in the presence of tunicamycin, ceils were 1134  MUTANT MONOCLONAL  ANTIBODIES 
pretreated  for 2 h with 2.5/Lg/ml of tunicamycin (27) before the isotope was added. 
Sodium  dodecyl sulfate  (SDS) acrylamide  gels were formed  either  in  phosphate or Tris- 
glycine buffers as described by Maizel (26). Gels were fixed and stained, treated  with Autofluor 
(National Diagnostic, Inc., Advanced Applications Institute Inc., Somerville, N  J), and analyzed 
by autoradiography using Kodak SB-5 film (Eastman  Kodak Co., Rochester,  NY). 
Reagents.  Protein A from Staphylococcus  aureus (protein A) was obtained from Sigma Chemical 
Co. Commercial  antisera  for typing mouse immunoglobulin class were obtained from Meloy 
Laboratories Inc., Springfield, VA, and for rat immunoglobulins  from Miles Laboratories  Inc., 
Research Products  Div., Elkhart,  IN. KLH was obtained from Sigma Chemical  Co. ICR-191 
was kindly provided by Dr. Howard Creech of the Institute for Cancer Research in Fox Chase, 
PA, and tunicamycin was provided by Dr. Robert Hamill,  Eli Lilly and Co. 
Results 
Isolation of Heavy Chain Mutants.  The hybridoma Ar13.4 produces IgGzbK antibody 
that binds the hapten p-azophenylarsonate. Subclones of this hybridoma producing 
mutant immunoglobulin molecules were identified using the same approach used to 
obtain constant region mutants from the MPC- 11 IgG2bK-producing mouse myeloma 
cell line.  Cells were mutagenized with the acridine half-mustard ICR 191 and cloned 
in soft agarose containing rabbit antibody that was specific either for the CH3 domain 
or for the subclass-specific antigenic determinants of the IgG2b constant region. Clones 
secreting intact immunoglobulin molecules became surrounded by a  visible antigen- 
antibody precipitate. Approximately 5% of the clones were not surrounded by such a 
precipitate. In preliminary experiments (28), some of these presumptive mutants were 
recovered  from  the  agarose  and  further  analyzed.  They were  found  either  (a)  to 
secrete  less  immunoglobulin than  the  parental  cells,  (b)  to  have lost  the  ability  to 
synthesize  detectable  amounts  of heavy  chains  (H-chains),  or  (c)  to  be  secreting 
immunoglobulin molecules that had structural changes resulting in a loss of reactivity 
with  the  selecting antiserum.  Loss of H-chain  production was  especially  common, 
presumably  due  to  the  segregation  of chromosomes that  occurs  during  the  early 
propagation of hybridomas. 
To  eliminate  the  need  to  recover  and  characterize  low  producers  or  H-chain 
nonproducers,  a  double  antibody  overlay  assay  was  used.  Clones  that  were  not 
surrounded by a visible antigen-antibody precipitate with the selecting antibody were 
marked.  The  dishes  were  then  overlaid  with  agarose-containing antibody reactive 
with  the whole IgG2b constant  region.  Only clones that  did not  react  with  the  first 
antiserum  and  did  react  with  the  second were  recovered.  The  medium  from  these 
clones  was  assayed  for  Ar-binding  antibody  by  facilitated  hemagglutination  of 
Ar:SRBC. Positive clones were further examined for their reactivity with the selecting 
antiserum  and with  monoclonal anti-IgG2b antibodies by inhibition  of hemaggluti- 
nation.  Eight  mutants  that  clearly  differed  from  the  parent  were  further  studied 
serologically and by polyacrylamide gel electrophoresis. 
Phenotypes of Mutant  Immunoglobulins.  Parental  and  mutant  cells  were  incubated 
with  [aSS]methionine,  and  the  secreted  immunoglobulins  were  analyzed  by  SDS- 
polyacrylamide gel electrophoresis. As can be seen in Fig.  1 (channel A), most of the 
antibody secreted by the parental Ar13.4 hybridoma was assembled into covalently 
linked  H2L2  molecules.  The  bands  that  migrate  slightly  faster  than  H2L2  may 
represent proteins that have not been completely glycosylated. Mutants ArM 17 and 
ARM19  (Fig.  1, channels B and C) were isolated in a single experiment and could be 
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FIG.  1.  SDS-polyacrylamide gel electrophoresis of secreted Ar13.4 and mutant immunoglobulins. 
Parent Ar13.4 (channel A) and mutant immunoglobulins (Arml7:B; ArM19:C; ArMI:D; ArM2:E; 
ArM16:F; ArM18:G; ArM20:H;  and ArM7:i) were biosynthetically  labeled by incubating 1.5 × 
106 cells in  1.5 ml of medium containing 50 Ci [~S]methionine  for 24 h. After removing cells by 
centrifugation, the labeled immunoglobulins were precipitated with haptenated Sepharose, lmmu- 
noglobulins were analyzed on a 5% polyacrylamide gel in the phosphate  buffer system of Maizel 
(26). 
Fic.  2.  SDS-polyacrylamide  gel  electrophoresis  of cytoplasmic  and  secreted  immunoglobulin. 
Parent  Ar13.4  (channels  A)  and  mutant  cell  lines  (ArM17:channels  B;  ArMl:channels C; 
ArM2:channels  D; ArM7:channels  E; ArM16:channels  F) were biosynthetically  labeled in  [35S]- 
methionine as described. Anti-Ar antibody was precipitated on haptenated Sepharose and eluted 
by boiling in SDS. C represents cytoplasmic immunoglobulin  and S represents secreted protein. 
Aliquots of each sample were reduced and alkylated and electrophoresed in the Tris-glycine SDS 
buffer system (26) through  a  10% polyacrylamide gel with a 3% stacking gel. Because of variable 
labeling efficiencies between cell lines, some channels represent longer exposures. 
H)  were  also from  a  single experiment, but  ARM16  and  ARM20  differ serologically 
(see below).  ARM17  and  ARM19  (channels  B  and  C)  have  H~L2  molecules that  co- 
migrate with the parent but differ in that small amounts of ilL molecules are secreted. 
The  remaining mutants  (channels  D-I)  are dramatically different  from  the  parent. 
Because the L-chains of all of these mutants have the same mobility as the parent on 
SDS gels, whereas, their H-chains are smaller than those of the parent  (Fig. 2), these 
changes in the covalent assembly and size of the secreted proteins are almost certainly 
due to changes in the structure of their heavy chains. 
The mutants with large changes in molecular weight secrete predominantly mole- 
cules that are incompletely convalently assembled (Fig. 1, channels D-I). The ratio of 
H~L2  to  HL  molecules  varies  over  a  broad  range.  Mutants  ARM16,  ARM18,  and 
ARM20  (channels  F,  G,  and  H)  secrete  barely  detectable  amounts  of covalently 
assembled H2L~. 
The  noncovalent  assembly of the secreted immunoglobulin  of representative mu- 
tants was examined by molecular-seiving in nondenaturing  buffers (Fig. 3, Table I). 
The polymers secreted by the cells do not always correlate with the covalent assembly 
patterns illustrated in Fig.  1. For example, ARM20 does not form significant amounts 1136  MUTANT MONOCLONAL ANTIBODIES 
FIG.  3.  Gel filtration profiles of Ar13.4  and representative mutants.  Secreted parent and mutant 
immunoglobulins biosynthetically labeled as for Fig. 1 were purified by affinity chromatography on 
haptenated Sepharose  4B. Approximately 3 ×  105 cpm of each purified antibody were mixed with 
the indicated markers  (blue  dextran, bovine serum albumin, ova|bumin, carbonic anhydrase, and 
myoglobin)  and chromatographed through a  1.5 ×  170-cm AcA44 (LKB) column at a linear flow 
rate of from 5-8 cm/h in Tris-saline.  The OD2s0 of each fraction was determined to locate peaks of 
the marker proteins,  and aliquots of each fraction were counted. Because of differences in flow rates, 
the markers do not chromatograph identically from run to run. The profiles have been aligned with 
respect to the BSA marker,  which elutes between H2L2 and HL molecules. 
Fro. 4.  The effect  of tunicamycin on  the migration of ARM1. Parent  Ar13.4  (channels  A)  and 
ArM1  (channels  B)  were  biosynthetically  labeled  with  [aSs]methionine  in  the  presence  (+)  or 
absence  (-)  of tunicamycin.  Cytoplasmic  immunoglobulin  was  precipitated  with  haptenated 
Sepharose,  reduced and alkylated, and analyzed as in Fig. 2. 
of  inter  H-chain  disulfide  bonds  (Fig.  1,  channel  H),  yet  is  secreted  as  an  H2L2 
molecule  in  which  the  H-chains  are  held  together  by  noncovalent  interactions, 
whereas  most  of the secreted  ArM2  is in the form of HL  half-molecules  (Fig.  2).  The 
noncovalent  assembly of mutants  representing each of the phenotypes  is summarized 
in Table I. 
Fig.  3  shows  reduced  intracellular  and  secreted  H- and  L-chains  of representative 
mutants.  The  H-chains  synthesized  by the parent  (channel  A)  and  ArM17  (channel 
B)  are very similar.  The  double  band  seen  in  the secreted  yZb heavy  chain  has  been 
attributed  to heterogeneity of glycosylation  (29).  Multiple distinct  H-chain bands  are 
seen  in the other mutants.  The  positions  of some of these bands  shift  strikingly  after 
secretion.  With  some  mutants,  the  multiple  cytoplasmic  bands  are  eliminated  by 
pretreating  the cells with tunicamycin  to prevent  N-linked glycosylation  (27).  This is 
illustrated for ArM 1 in Fig. 4. The nonglycosylated parental  H-chain migrates slightly 
more rapidly  than  the glycosylated chain  (channel  A). The  double  H-chain  bands  of 
ArM1  (channel  B)  are reduced  to a  single band  in the presence of tunicamycin. DALE  E.  YELTON  AND  MATTHEW  D.  SCHARFF 
TABLE  I 
Relative Amounts of H2L2 and HL Secreted 
H2L2  HL 
%  % 
Ar13.4  100  0 
ArM 17  100  0 
ArM 1  27  73 
ArM2  18  82 
ARM16  100  0 
ARM20  100  0 
ArM7  18  82 
Biosynthetically labeled immunoglobulins from parent and mutant cell lines 
were  subjected  to  gel  filtration with  AcA44,  as  described  for  Fig.  2.  The 
percentage of count3 in each peak are listed.  For mutant ARM2, the counts in 
the small peak between H2L2 and HL  (that might correspond to the middle 
band in channel E, Fig.  1) are disregarded. 
1137 
Flo.  5.  The effect  of tunicamycin on migration ARM7. Parent Ar13.4  (channels A  and B)  and 
ArM7 (channels C and D) were labeled with (+) and without (-) tunicamycin as in Fig. 4. After 
labeling, samples were divided, and immunoglobulins were precipitated either by indirect immu- 
noprecipitation  (channels A  and  C)  or  hapten-Sepharose  (channels  B  and  D).  Reduced  and 
alkylated samples were electrophoresed and autoradiographed as in Fig.  2. 
Fie.  6.  Comparison of ArM1 and M3.11.  Immunoglobulins (intracellular) were biosynthetically 
labeled, immunoprecipitated, reduced, and electrophoresed as described for Fig.  2. The channels 
represent the following:  A:Arl3.4 parent; B:MPC-11; C:ArM1; D:M3.11. 
For other mutants,  tunicamycin  treatment  did not eliminate  the complexity  of the 
electrophoretic  pattern.  The  slowly  migrating  band  in  the cytoplasm  of ArM2  (Fig. 
3,  channel  D  [c])  remained  after  tunicamycin  treatment.  With  mutant  ARM7, 
tunicamycin  changed  the pattern  of heavy chain bands, but at least two and probably 
three bands were detected in the presence of the inhibitor  (Fig. 5), suggesting that this 1138  MUTANT  MONOCLONAL ANTIBODIES 
mutant synthesizes more than one heavy chain polypeptide. Northern blots of ArM7 
RNA  also  reveal three  mRNA bands  of similar size that  hybridize  to  a  y2b probe 
(Sau-Ping Kwan, unpublished results). The multiple heavy chain bands in Fig. 5 were 
precipitated by both antisera and antigen,  indicating that all forms of the H-chains 
participate in the interaction with antigen.  This is true for all of the mutants  (data 
not shown). 
Some of the mutants illustrated  above are remarkably similar to those that  have 
been reported for mutants of the MPC-11  cell line  (4).  In Fig. 6, the electrophoretic 
mobility of the  ArM1  heavy chain  (channels  C)  is  compared with  that  of M3.11 
(channel D), an extensively studied mutant of MPC-11  (9, 10, 24). The double heavy 
chain band, its conversion to one band by tunicamycin (Fig. 4), and the noncovalent 
assembly of M3.11  and ArM1  (Table I and Fig.  3)  are similar. There is a  difference 
in the migration of the nonglycosylated form of the heavy chains of these two mutants 
that may be due to a small difference in their size. 
Characterization of Rat  Monoclonal Anti-IgGgb Antibodies.  To  serologically  map  the 
defects in the mutants of Arl 3.4, we generated a battery of rat monoclonal antibodies 
that  react  with  the  mouse  IgGzb immunoglobulin.  Rats were  immunized  with  the 
MPC- 11 myeloma protein, and their spleen cells were fused to a nonproducing mouse 
myeloma cell line.  15 cloned,  stable rat  hybridomas that  made high  titer antibody 
against mouse IgG2b were examined for their reactivity with various mouse myeloma 
proteins and for their ability to cross-inhibit each other in competitive binding assays. 
Three of these have been reported previously (16):  187, which reacts with the constant 
region of mouse K  L-chains;  116, which recognizes all of the IgG subclasses equally; 
and 168, which reacts preferentially with IgGzb. 116 and 168 are further characterized 
below along with additional rat monoclonal antibodies that bind different antigenic 
determinants. These were identified by their distinctive reactivities with the subclasses 
of mouse IgG and their inability to inhibit each other's binding. 
The availability of myeloma mutants derived from MPC-11, whose structures had 
been extensively studied,  made it possible to localize the determinants recognized by 
each anti-IgG2b monoclonal. Two mutants with large deletions, one in CH 1 (B50-10.1) 
(11-13)  and  the  other  encompassing  all  of CH3  (M3.11)  (10),  divided  the  IgG2u 
constant  region  into  three  sections  roughly  equivalent  to  the  three  domains.  A 
determinant  could be assigned to one of these segments, depending on whether the 
antibody bound  to either or both of these mutants.  The parent  Ar13.4  protein  was 
bound  to  polyvinyl plates,  and  the  ability of the  M3.11  and  B50-10.1  mutants  to 
inhibit  binding  of each  biosynthetically  labeled  anti-IgGzb monoclonal  was  deter- 
mined  (Table II).This approach depends upon  the assumption that, when a  mono- 
clonal does not react with a deletion mutant, its determinant is contained within the 
deletion.  It is possible, of course,  that  a  deletion  (or any mutation)  could  induce  a 
conformational change in the protein, destroying the tertiary structure recognized by 
an antibody, even though the determinant's primary sequence remains. Because the 
domains of antibody molecules fold relatively independently of one another, we hoped 
the choice of the BS0-10.1  and M3.11 myeloma mutants, whose deletions are restricted 
to a  single domain,  would  avoid this  problem. Another  potential  source of error is 
that a monoclonal could bind two similar determinants in the homologous regions of 
different domains. Although we believe that such complications are unlikely, it should 
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TABLE  II 
Reactivity of Rat Anti-IgG2o Monoclonals with MPC-11 Mutants 
Percent inhibition of binding by 
Mab  B50-10-. 1  M3.11 
(-Cn  i)  (-Cn3) 
116  8  94 
180  98  90 
196  93  9 
178  99  0 
31  91  0 
168  100  0 
Ar13.4  was adsorbed to polyvinyl chloride microtiter wells, and  [3sS]biosyn- 
thetically  labeled  anti-IgG2b  was  added  in  the  presence  of each  mutant 
immunoglobulin or no inhibitor. Mutant immunoglobulins were concentrated 
20-fold by 50% NaSO4 precipitation from culture supernatants,  and controls 
consisted of unused growth medium concentrated in the same way. Results are 
the  means  of triplicate  determinations  expressed  as  percent  inhibition  as 
control  epm  (no  inhibitor  control)  -  experimental  cpm  (with  inhibitor)/ 
control cpm X 100. Background counts bound to wells not coated with antigen 
have been subtracted. 
TABLE  III 
Protein A Competes with Monoclonal 196for Binding to Mouse IgG2b 
Mab  cpm bound in ab-  cpm bound in presence of 
sence of protein A  protein A 
187  26,224  29,567 (113%) 
196  14,272  2,292 (11%) 
178  15,777  11,495 (71%) 
31  10,967  12,297 (112%) 
168  2,973  2,649 (86%) 
Ar13.4  (1  #g/well)  was  bound  to  polyvinyl chloride  microtiter  wells  via 
Ar:KLH antigen and probed with the indicated aS-labeled monoclonal anti- 
IgG2b antibodies  in  the  presence  and  absence  of protein  A  (10  #g/well; 
approximately 30-fold  molar excess over IgG2b). Diluent for this  assay  was 
Tris-saline,  pH 8.0, with  1% BSA because  protein A requires alkaline pH to 
bind to IgG2b (32). Counts represent mean of triplicate determinations. 
analysis of additional  mutants  studied with these antibodies. 
B50-10.1  protein  does  not  inhibit  the  binding  of rat  monoclonal  116,  suggesting 
that  116  recognizes  an  antigenic  determinant  on  the  CH1  domain  (Table  II).  180's 
binding  is inhibited  by both  mutants,  suggesting  that  it  binds  within  the structural 
segment  the two  mutants  share.  This segment  includes  the CH2  domain,  hinge,  and 
possibly  some C-terminal  sequences  in  Cal.  Although  these  two  mutants  also  share 
the same variable region, all of the rat monoclonals were shown to react with constant 
rather  than  variable region determinants  by methods  described previously  (16).  Rat 
monoclonals  196,  178,  31,  and  168  are all inhibited  by B50-10.1  and  not  by M  3.11. 
It was concluded that  they recognize determinants  on the CH3 domain,  although,  as 
discussed above, we cannot rule out reactivity with a  determinant  on the CH2 domain 
that  changed  its conformation  as a  result of the CH3 deletion. 
We  attempted  to  further  define  the  site  of reactivity  of these  putative  anti-CH3 1140  MUTANT MONOCLONAL ANTIBODIES 
TABLE  IV 
Reactivity of Rat Monoclonal Anti-IgG2b with Ar l3. 4 and Mutant Immunoglobulin 
Parent  Mutants 
Ari3.4  ARM17  ArM1  ArM2  ArM7  ARM16  ARM20 
tool wt (X 10  -a)  (55)  (55)  (39)  (41)  (39)  (39)  (39) 
Mab  Percent cpm bound 
116(CH 1)  100  71  106  98  83  99  91 
180(Cn2)  100  46  93  74  43  0  0 
196(CH3)  100  0  0  0  0  1  3 
178(Cn3)  100  0.5  0  0  0  10  12 
31  (Cn3)  100  0  0  0  0  96  97 
168(Cn3)  100  130  2  0  3  128  23 
Parent and mutant immunogtobulins from culture supernatants (100/xl) were bound to polyviayl chloride 
microtiter wells via Ar:KLH antigen, after which wells were thoroughly washed, ass-labeled  rat monoclonals 
were  added  in  excess, and  the  counts  bound  to each  well were  determined.  Each  assay  was  done  in 
triplicate.  The results are expressed for each monoclonal as the percentage of counts bound to the Ar13.4 
parent immunoglobulin when it was at a concentration (30 #g/ml) that saturated  all Ar:KLH sites. For 
some  monoclonals  (ArMI7 and  ARM7), less antibody  is secreted  by the mutant,  and  probably  not all 
antigen  sites  are  saturated.  The  approximate  H-chain  molecular weights  listed  for  the  mutants  were 
determined  for the most  rapidly migrating H-chain bands  in  Fig.  2.  The location of the determinants 
recognized  by each Mab is indicated in parentheses. 
monoclonals  by  determining  whether  protein  A  competes  with  any  of  them  for 
binding to  IgG2b.  Protein  A  has  been shown  by x-ray crystallography  to bind  to  the 
Fc portion  of human  IgG at  the CH2-CH3 junction  (30).  As can be seen in Table  III, 
when  IgGzb is  pretreated  with  protein  A, only  196  is  prevented  from  binding.  This 
would suggest  that  the  196 determinant  is located  in the N-terminal  part  of CH3  (or 
C-terminal  CH2).  Despite  the  fact  that  protein  A  has  a  molecular  weight  of 45,000 
and  induces  conformational  changes  in  the  Fc  region  (31),  it  does  not  inhibit  the 
binding of 178,  31, and  168. 
Localizing the Deletions in the Mutant Monoclonal  Antibodies.  The  rat  anti-IgG2b  mon- 
oclonal antibodies  were used  to  determine  roughly  what  part  of the constant  region 
had  been  deleted  from  the  mutants  derived  from Ar13.4.  Ar:KLH  was  adsorbed  to 
polyvinyl  plates.  Culture  supernatants  from  the  mutants  were  then  incubated  with 
the antigen-coated plates. After washing, biosynthetically labeled (35S) rat monoclonal 
antibody  was  added  to each  well.  Because  different  rat  monoclonal  antibodies  were 
labeled  to  different  specific activities,  the  binding  to  a  mutant  for each  monoclonal 
was  calculated  as  the percent  of counts  that  bound  to saturating  amounts  of Ar13.4 
parent  (Table  IV).  Because  the  mutants  and  parent  are  polymerized  to  different 
degrees and may bind to the antigen-coated plates with different avidities, we consider 
this  a  qualitative  assay.  In  each  case,  however,  the  reactivity  with  one  or  more 
monoclonals (vertical column, Table IV') reveals that adequate amounts of the mutant 
protein  bound  to  the  plate.  ARM1,  ARM2,  and  ArM7  resemble  M3.11  (Table  II)  in 
that  they  do  not  react  with  any  of the  four  rat  monoclonals  assigned  to  the  CH3 
domain.  Based on their molecular weights  (Table IV), these mutants  have undergone 
deletions equal to approximately one domain.  Because preliminary studies  (Sau-Ping 
Kwan,  unpublished  observations)  indicate  the  messenger  RNA  that  hybridize  to  a 
y2b probe are approximately normal in size, we would predict that these three mutants 
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most of their Cn3 domains (10). ARM16  and ARM20 do not react with  180 and  196, 
which we have assigned to the CH2  and  CH3  domains, respectively. They do react 
weakly (5-6 times background) with 178 and strongly with 31, both of  which recognize 
CH3  determinants.  Although  the  gel  pattern  in  Fig.  1 suggests  that  ARM16  and 
ARM20  are similar,  168 reproducibly distinguishes  between them  (Table IV).  Fur- 
thermore, the y2b mRNA present in these two mutants differ in size (Sau-Ping Kwan, 
unpublished observations). Because ArM 16 and ARM20 are missing approximately a 
domain equivalent, we would predict that they have undergone an internal deletion 
involving all or most of CH2, due either to deletion at  the DNA level or a  splicing 
defect. The loss of reactivity with 196 and greatly decreased reactivity with 178 could 
be due to loss of part of CH3 or conformational changes resulting from the abnormal 
covalent joining of the hinge or part of the N-terminal CH2 to the CH3 domain. 
ArM 17 is grossly abnormal serologically (Table IV), but its size is very similar to 
the parent, and its assembly pattern (Fig.  1) is only slightly abberrant. Its lesion also 
appears to include CH3 sequences because it lacks the determinants seen by mono- 
clonals 196, 178, and 31. The increased reactivity of 168 with ARM17  is reproducible. 
Similar phenomena here have been seen in other systems analyzed with monoclonals, 
where determinants close to sequence changes sometimes show increased reactivity 
(33). The ArM17 protein does not react in agar diffusion with rabbit antibody specific 
for the y2b CH3 domain and reacts only weakly with IgG2- and IgG2b-specific antisera. 
Although  we  have  been  unable  to  detect  a  reaction between  ARM17-  and  IgG2a- 
specific antisera,  it  might  represent  a  subclass  switch  mutant  producing a  hybrid 
IgG2b-~a molecule (4). In our experience with similar myeloma mutants, these proteins 
have often proved difficult to classify with standard  reagents.  ARM17  will  require 
extensive chemical characterization before we can determine the nature of its defect. 
It is interesting that  196, the monoclonal whose binding is inhibited by protein A, 
does not react with any of the mutants. This could be because the conformation of 
the antigenic determinant recognized by 196 is readily changed by sequence changes 
in CH2 or CH3.  For example,  196 might recognize an antigenic determinant formed 
by the interaction of CH2  and  Cri3 sequences. It  is  also possible  that  it recognizes 
sequences  that  are  deleted  from  all  of the  mutants  because  they  are  the  major 
antigenic determinants recognized by the rabbit antisera used to select these mutants. 
Effector Functions of Mutant Immunoglobulins.  We determined which of the effector 
functions exhibited by IgG2b were retained by each of the hybridoma mutants for two 
reasons.  First,  although  controversy  exists,  several  reports  have  assigned  specific 
functions to individual domains (6). Knowledge of activities of each mutant offers an 
independent test of the structures we inferred from their reactivity with the rat anti- 
IgG2b monoclonals.  Second,  and  more  importantly,  we  might  be  in  a  position  to 
further refine our knowledge of immunoglobulin effector functions by determining 
the structure of mutants with interesting properties. The antigen-binding activity of 
mutant monoclonal antibodies makes studying their effector functions not only very 
convenient but possibly more relevant to physiologic antibody functions than studies 
with chemically aggregated proteolytic fragments. We examined the ability of the 
Ar13.4 mutants to bind protein A, bind mouse macrophage Fc receptors, and mediate 
complement-dependent lysis of SRBC. 
To study their interaction with protein A, parental and mutant proteins bound to 
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TABLE V 
Interaction of Protein A  with Mutant Irnmunoglobulins 
Immunoglobulin  187 Bound  Protein A Bound 
Culture medium  cpm  cpm 
Ar 13.4  9,244  8,313 
ArM 17  4,390  46 
ArM 1  10,683  45 
ArM2  6,250  57 
ArM7  5,254  47 
ARM20  10,119  68 
ArM i6  9,785  88 
X63/AgS.653  351  53 
Purified Ar13.4 
100 ~g/ml  13,273  10,173 
10/~g/ml  11,666  9,916 
1 #g/ml  3,514  5,379 
0.1/lg/ml  816  637 
Parent and mutant immunoglobulins were bound to microtiter wells, as in 
Table IV, except using Tris-saline  as in Table III. Excess asS-labeled 187 (anti- 
k constant region) monoclonal or 125I-labeled  protein A was added to each 
well, after which wells were washed and counted in a  Beckman LS-9000. 
Because 187 is in excess, the amount of S~S counts reflects the relative amounts 
of anti-Ar antibody bound to each well. It is clear that adequate amounts of 
each mutant bind. 12~I-labeled  protein A was not in excess. Protein A was 
iodinated by the glycouril method (35), using 10 ~g of glycouril per 20/lg of 
protein A and I mCi of 12sI (Amersham Corp., Arlington Heights, IL). 
(Mab  187)  to determine the relative amount of immunoglobulin  in each well or 125I- 
labeled protein A  (Table V).  None of the  mutants bound protein A.  This result is 
consistent with  the  previous results  that  protein A  interfered with  the  binding of 
monoclonal 196 to IgG2b and that  196 does not bind to any of these mutants. 
To determine whether the mutant proteins would bind macrophage Fc receptors, 
parent and mutant proteins were incubated with Ar:SRBC. The antibody-sensitized 
SRBC were then washed and incubated with FC-1, a  macrophage cell line (34)  that 
had adhered to cover slips. After washing away the unattached SRBC, the coverslips 
were  scored  for  rosettes  (Table VI).  Only the  parent  and ARM17  formed  rosettes. 
Facilitated hemagglutination assays showed that approximately the same amount of 
each mutant bound to the  SRBC.  SRBC  sensitized with sixfold less parent protein 
formed rosettes efficiently (Table VI). 
IgG2b fixes  complement by the  classical pathway  and  mediates complement-de- 
pendent cytolysis, although less efficiently than IgM antibodies. C lq,  the first com- 
ponent of complement, is reported to associate with the CH2 domain (6). We examined 
the  ability of the  parent and mutant proteins to  lyse Ar:SRBC in the  presence of 
guinea pig complement absorbed with  protein A  to  remove guinea pig antibodies. 
ARM1, ARM2, ARM7, and ARM17 all lysed SRBC, though not always as efficiently as 
the parent, When ArM1  H2L2  and HL molecules were separated, the HL molecules 
could not  detectably lyse  the  RBC,  whereas  the  fully assembled molecules did.  A 
control IgG1 anti-Ar hybridoma was also unable to lyse Ar:SRBC. ARM16, ArM 18, 
and ARM20 were  the  only mutants that  did not  lyse the  SRBC.  This was  true of 
ARM16,  even when  the  cells  were  incubated with  over  16  times  as  much  ARM16 DALE  E.  YELTON  AND  MATTHEW  D.  SCHARFF  1143 
TABLE  VI 
Binding of Mutant Immunoglobulin to Macrophage Fc Receptors 
Percent of macrophages bear- 
Immunoglobulin coating Ar:SRBC  ing five or more SRBC 
Ar13.4 
200/xg  95 
75/xg  95 
20/~g  80 
5/Lg  5 
ArMl(125 #g)  5 
ARM2(125/xg)  5 
ARM7(125/xg)  5 
ArMI7(125 p,g)  85 
ARM16(125 p,g)  5 
250/tl of freshly prepared Ar:SRBC (not gluteraldehyde fixed) were incubated 
with the indicated amounts of purified anti-Ar immunoglobulins for  1 h  at 
25°C. Antibody-sensitized RBC were washed twice and resuspended as a  10% 
suspension in fresh culture medium. The macrophage-like cell line FC-1 had 
been allowed to adhere at a  low density to glass coverslips for 2 h, after which 
unattached cells were rinsed off and the sensitized RBC  (2%  suspension, 0.5 
ml/coverslip) were allowed to settle for 20 rain at  25°C onto the coverslips. 
Coverslips were  rinsed by immersing several times in  DME  and scored for 
rosettes. A  rosette was defined  as a  macrophage bearing five or  more RBC 
(34), but the rosetted macrophages were usually completely covered and had 
often phagocytized RBC as well. The background reported as 5% is felt to be 
due  to  RBC  occasionally trapped  between  between  adjacent  macrophages. 
Ar:SRBC with no immunoglobulin attached and unhaptenated SRBC incu- 
bated with 200 #g Ar 13.4 immunoglobulin produced similar backgrounds. 
protein as the minimum amount of parental protein required for lysis.  This result is 
consistent with the monoclonal serology, suggesting that ARM16 lacks a large portion 
of the CH2 domain. 
Discussion 
The hybridoma technology has  made  it possible to generate homogeneous anti- 
bodies  to  many  biologically and  medically important  antigens  (2).  Because  large 
amounts  of monoclonal  antibodies  can  be  produced  and  the  supply  renewed  as 
needed, many investigators are examining their diagnostic and therapeutic uses. The 
potential availability of human monoclonals (36-38)  has led to a  reexamination of 
the usefulness of passively administered antibody in the prevention, diagnosis,  and 
treatment  of disease.  Among  the  significant  advances  already  achieved  are  the 
generation of antibodies  that  recognize many human  differentiation antigens  (39). 
Antibodies that recognize antigens on tumor cells could provide a means of identifying 
sites of metastatic spread or even delivering cytotoxic agents specifically. Monoclonal 
antibodies coupled to plant  or bacterial toxins have been shown  to kill carcinoma 
cells, specifically in vitro (40, 41). In a  particularly dramatic example of the thera- 
peutic use of monoclonal antibody, Miller et al.  (42)  recently reported successfully 
treating  a  patient  with  a  widespread  B  cell  lymphoma  unresponsive  to  current 
chemotherapy by injecting a mouse monoclonal antibody that recognized the idiotype 
of the lymphoma immunoglobulin. 
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structural  and  functional properties of immunoglobulins.  Bivalent  antibodies  often 
modulate surface antigens so that they are no longer present on the cell.  Monoclonals 
bearing cytotoxic agents or radioactive labels will combine not only with the intended 
target  cells  but  also  with  cells  of the  immune  system  bearing  Fc  receptors  either 
through cytophilic interactions  or by forming immune  complexes with  circulating 
antigens. Circulating immune complexes might initiate dangerous allergic reactions, 
and  deposition  of immune  complexes  can  damage  nonlymphoid  tissues,  such  as 
kidney. 
A solution to these problems analogous to preparing Fab fragments from conven- 
tional  antisera  is  to  identify  hybridoma  mutants  producing  structurally  altered 
immunoglobulins  that  form  only HL half-molecules or  do  not  exhibit  the  normal 
immunoglobulin  functions.  Such  mutant  monoclonal  antibodies  would  provide  a 
homogeneous reagent that would be continuously renewed, thus, retaining the major 
benefits of the hybridoma technology. The techniques we had used to identify such 
immunoglobulins produced by mutant mouse myeloma cells  were slightly modified 
and  applied  successfully to  hybridomas. Out of ~17  ×  103 clones examined,  eight 
(0.05%) were producing structurally altered immunoglobulins that did not react with 
the selecting antiserum but still bound antigen. This number does not include variants 
that produced little or none of either immunoglobulin chain or mutants that had lost 
the ability to bind  antigen  because these would have been  discarded  in  screening. 
This frequency is at least  10-fold lower than the frequency with which similar mutants 
have been isolated from mouse myeloma cells  (4), although it is still  high enough to 
make it relatively easy to obtain mutants. The difference could reflect a  difference in 
the stability of the immunoglobulin genes in these cells,  but it is more likely due to 
the use of different selecting antisera and the more stringent requirements imposed by 
the double overlay technique.  For example, it is very likely that some mutants went 
undetected  because  they retained  enough determinants  to  react  with  the  selecting 
antiserum.  Others might have been sufficiently altered not to react with the second 
antiserum and were discarded as heavy chain nonproducers or nonsecretors. Even a 
mutant  frequency of 0.05%  reflects a  high degree of instability  for genes in animal 
cells. 
Using  an  IgM-producing hybridoma, Kohler  and  Schulman  (43) also  identified 
mutants  producing structurally  altered  immunoglobulins.  However,  their  cell  line 
generated mutants  at  much lower frequencies.  Schulman et  al. 2 recently examined 
another IgM-producing hybridoma and found mutants at frequencies similar to those 
reported  here.  We  have  done  a  few  experiments  with  another  IgG2b-producing 
hybridoma, and it also generates mutants a high frequencies (28). 
Although we used mutagenesis in these experiments  in the hope of increasing the 
yield of mutants, we do not have any evidence that it was necessary or effective. The 
recovery  of two  pairs  of phenotypically  identical  mutants  (ARM17  and  ARM19; 
ARM16  and  ARM18)  in  this  small  sample  suggests  that  some  mutants  could  have 
existed in the population before mutagenesis. 
Most  of the  mutants  isolated  with  IgG2b- and  CH3-specific antisera  appeared  to 
contain deletions  in  the C-terminal portion of the heavy chain.  It is  not surprising 
that these two different antisera should select such similar mutants. In our experience, 
2  Shulman, M. J., C. Heusser, C. Filkin, and G. Kohler. Mutations affecting  the structure and function 
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many of the IgG2b-specific determinants appear to reside in CHa. M3.11, the myeloma 
mutant that lacks exclusively CHa, does not react with either commercial anti-IgG2b 
antisera prepared in goats or the rabbit IgG2b-specific antisera used in these experi- 
ments, Herzenberg et al. (44) have shown that most of the polymorphic determinants 
recognized by mouse alloantisera  are confined  to  the  carboxy-terminal half of the 
immunoglobulin molecule. Most of the rat anti-mouse IgG2b monoclonal antibodies 
that we generated also react with the CH3 domain. Mutants with alterations in other 
parts of the molecule presumably could be selected with antisera directed at different 
portions of the constant region. Preparation of such antisera might be facilitated by 
immunizing with mutant  proteins lacking the normally immunodominant  determi- 
nants. 
We do not know the molecular mechanisms responsible for generating the mutant 
phenotypes  that  we  identified.  Some  mouse  myeloma  mutants  with  C-terminal 
deletions  are  the  result  of point  mutations  or  frame shifts  that  lead  to  premature 
terminations (4). Preliminary studies examining the size of the H-chain mRNA of the 
mutants  reported  here  suggest  that  more  complex  events  are  occurring  in  some 
mutants  (Sau-Ping Kwan, unpublished observations). The origin of the multiple H- 
chains in some mutants  (ARM2 and ArM 17)  might provide more information about 
the expression of immunoglobulin genes. 
As noted above, mutant monoclonal antibodies could be useful in further charac- 
terizing the structural  bases of effector functions.  All but one of the mutant  mono- 
clonals reported here contain  large deletions.  This is probably because the loss of a 
single antigenic determinant would not be detected by the antisera used. In addition, 
the mutagen used (if effective) favors production of frame shift and deletion mutants 
(4).  Our  aim  in  examining  the  effector  functions  of these  deletion  mutants  was 
primarily to support the inferences made from the serological mapping of the deletions 
in  the Ar13.4  mutants.  Even this  small group of grossly altered proteins,  however, 
turned out to contain members (ARM17  and ARM1)  that upon further study might 
yield new information about the structural  basis of biological activity. For example, 
protein A has been reported to inhibit the uptake of IgG2b by macrophages, suggesting 
that protein A and Fc receptors might recognize the same part of the immunoglobulin 
molecule  (45).  ARM17  does not  bind  protein  A  but  does bind  the  macrophage Fc 
receptor, indicating that protein A and Fc receptors do not bind to identical sites. If 
ARM17  proves to be a  IgG2u-2a hybrid,  it  would  be interesting  to know whether  it 
binds  the  IgG2b or IgG2a Fc receptor  (34).  ArM1  does  not  bind  to  macrophage Fc 
receptors. As has been described  above, this mutant  is very similar to  M3.11  in  its 
serology and assembly, but its heavy chain may be slightly smaller (Fig. 6). Because 
M3.11  does bind  to  Fc receptors when  artificially aggregated  (8),  it  is  conceivable 
that  ArM1  is  missing  a  functionally  important  part  of the  molecule  retained  by 
M3.11.  Studies  are  now  under  way  to  compare  these  proteins  functionally  and 
structurally. 
Although  more mutants like these could be produced  in an  attempt to find ones 
that defined functionally important regions, it seems preferable to identify mutants 
with point mutations or very small deletions. These may make it possible to identify 
precise sequences responsible for each effector function.  In addition,  these  mutants 
with  large  deletions  have shortened  half-lives in  the  circulation  (Susan  B.  Roberts 
and D. E. Yelton, unpublished observations) and accumulate poorly in ascites, making 1146  MUTANT MONOCLONAL ANTIBODIES 
it  difficult  to  prepare  large  amounts  of  mutant  proteins.  One  solution  to  these 
problems is to select mutants  with small mutations using antisera made specific for 
small regions by sequential  absorption  on  multiple  mutant  proteins.  However,  the 
observation  that  monoclonal  196  competes  with  protein  A  for  binding  to  IgG2b 
suggests  a  strategy  for obtaining mutants  with  small mutations  at  sites of greatest 
biological interest. Ifa large battery ofmonoclonal anti-immunoglobulins is generated, 
those that  interfere with  a  particular effector function  can  be identified. These can 
then be mapped with respect to each other by cross-inhibition studies and those that 
recognize  independent  antigenic  determinants  used  to  identify mutants.  Based  on 
studies  with  influenza  virus  (46),  many  of these  are  likely to  be  point  mutations 
resulting in single amino acid substitutions.  The  mutant  immunoglobulin  can  then 
be examined for its ability to carry out  effector functions.  Once  a  monoclonal  that 
identifies mutations  in  important  sequences  has  been  identified, it  can  be  used  to 
identify similar mutations in any monoclonal of that particular subclass. 
Summary 
Somatic cell mutants  with deletions in the immunoglobulin constant  region were 
isolated from an IgG2b Ar-binding hybridoma. Rat anti-mouse immunoglobulins were 
used to identify the sites of the deletions. The mutant  monoclonal antibodies differ 
from  the  parental  molecule  in  their  assembly  states  and  are  defective  in  various 
immunoglobulin activities, making them potentially more useful reagents. 
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